Hirnmetastasen und Meningeosis carcinomatosa solider Tumoren

Zerebrale Metastasen oder eine Meningeosis neoplastica treten im Verlauf einer Tumorerkrankung relativ häufig auf und gehen auch heute noch mit einer relevanten Morbidität und Mortalität einher. Insbesondere die Therapierbarkeit zerebraler Metastasen hat sich allerdings in den letzten 20 Jahren erheblich verbessert. Der Artikel fasst die wichtigen Entwicklungen in der Diagnostik und Therapie zerebraler Metastasen und der Meningeosis neoplastica zusammen.

Kernaussagen

• Die Therapierbarkeit zerebraler Metastasen hat sich in den vergangenen 2 Dekaden grundlegend verbessert.

• Die Radiochirurgie sowie die Therapie mit Immuncheckpointinhibitoren haben die Behandlung revolutioniert.

• Die molekulare Charakterisierung des Gewebes macht heute die Anwendung von „targeted Therapies“ möglich.

• Eine zerebrale Metastasierung ist heute kein Ausschlusskriterium mehr für die Teilnahme an klinischen Studien.

• Die operative Resektion einer großen Raumforderung kann auch bei multipler Metastasierung sinnvoll sein.

• Therapieoptionen bei Meningeosis carcinomatosa sind eine systemische Therapie, eine Bestrahlung oder eine intrathekale Chemotherapie.

• Mangels prospektiver Daten erfolgt die systemische Therapie der Meningeosis carcinomatosa (konventionelle Chemotherapie/targeted therapies/Immuntherapien) oft analog der Therapie bei zerebralen Metastasen der jeweiligen Tumoren.

• Therapieentscheidungen sollen interdisziplinär getroffen werden.

Schlüsselwörter

Hirnmetastasen - metastasierte Tumorerkrankung - Meningeosis neoplastica - Ganzhirnbestrahlung - zerebrale Metastasen

Publikationsverlauf

Artikel online veröffentlicht:
21. September 2023

• Literatur

• 1 Aizer AA, Lamba N, Ahluwalia MS. et al. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol 2022; 24: 1613-1646
• 2 Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012; 14: 48-54
• 3 Berghoff AS, Brastianos PK. Toward Precision Medicine in Brain Metastases. Semin Neurol 2018; 38: 95-103
• 4 Cagney DN, Martin AM, Catalano PJ. et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 2017; 19: 1511-1521
• 5 Kaufmann TJ, Smits M, Boxerman J. et al. Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol 2020; 22: 757-772
• 6 Le Rhun E, Guckenberger M, Smits M. et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 2021; 32: 1332-1347
• 7 Seidel S, Wehner T, Miller D. et al. Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurological Research and Practice 2022; 4: 45
• 8 Kim PH, Suh CH, Kim HS. et al. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. European Radiology 2021; 31: 4114-4129
• 9 Redmond KJ, De Salles AAF, Fariselli L. et al. Stereotactic Radiosurgery for Postoperative Metastatic Surgical Cavities: A Critical Review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines. International Journal of Radiation Oncology, Biology, Physics 2021; 111: 68-80
• 10 Minniti G, Niyazi M, Andratschke N. et al. Current status and recent advances in resection cavity irradiation of brain metastases. Radiation Oncology 2021; 16: 73
• 11 Mahajan A, Ahmed S, McAleer MF. et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 1040-1048
• 12 Brown PD, Gondi V, Pugh S. et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 2020; 38: 1019-1029
• 13 Tawbi HA, Forsyth PA, Hodi FS. et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 2021; 22: 1692-1704
• 14 Le Rhun E, Devos P, Weller J. et al. Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. Neuro Oncol 2021; 23: 1100-1112
• 15 Le Rhun E, Weller M, Brandsma D. et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 2017; 28: iv84-iv99
• 16 Remsik J, Chi Y, Tong X. et al. Leptomeningeal metastatic cells adopt two phenotypic states. Cancer Rep (Hoboken) 2022; 5: e1236
• 17 Grossman SA, Finkelstein DM, Ruckdeschel JC. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993; 11: 561-569
• 18 Hitchins RN, Bell DR, Woods RL. et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655-1662
• 19 Glantz MJ, Jaeckle KA, Chamberlain MC. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5: 3394-3402
• 20 Boogerd W, van den Bent MJ, Koehler PJ. et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004; 40: 2726-2733
• 21 Le Rhun E, Mailliez A, Wallet J. et al. Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial. Annals of Oncology 2018; 29: viii122
• 22 Le Rhun E, Preusser M, van den Bent M. et al. How we treat patients with leptomeningeal metastases. ESMO Open 2019; 4: e000507
• 23 Yang JCH, Kim SW, Kim DW. et al. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol 2020; 38: 538-547
• 24 Zou Z, Xing P, Hao X. et al. Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study. BMC Med 2022; 20: 12
• 25 Morikawa A, de Stanchina E, Pentsova E. et al. Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases. Clin Cancer Res 2019; 25: 3784-3792
• 26 Glitza IC, Smalley KSM, Brastianos PK. et al. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res 2020; 33: 527-541
• 27 Brastianos PK, Strickland MR, Lee EQ. et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun 2021; 12: 5954
• 28 Brastianos PK, Lee EQ, Cohen JV. et al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med 2020; 26: 1280-1284
• 29 Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncology 2010; 11: 871-879
• 30 Cohen-Pfeffer JL, Gururangan S, Lester T. et al. Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration. Pediatric neurology 2017; 67: 23-35
• 31 Bonneau C, Paintaud G, Trédan O. et al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 2018; 95: 75-84
• 32 Chamberlain M, Junck L, Brandsma D. et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 2017; 19: 484-492